당뇨황반부종에서 유리체강 내 애플리버셉트 주입술 후 할러층두께: 1개월 변화 = Haller Layer Thickness after Intravitreal Aflibercept Injection in Diabetic Macular Edema: 1 Month Change

국문 초록 (Abstract)

목적: 유리체강 내 애플리버셉트 주입술 후 황반하 할러층두께, 황반하 맥락막두께, 중심황반두께의 변화를 알아보고자 하였다.
대상과 방법: 2016년 12월부터 2021년 6월까지 유리체강 내 애플리버셉트 주입술을 처음 시행받은 당뇨황반부종 환자 36명을 대상으로 후향적 분석을 하였다. 스펙트럼영역 빛간섭단층촬영을 이용해 측정된 황반하 할러층두께, 황반하 맥락막두께, 중심황반두께의술 전, 술 후 1개월째 변화를 비교 분석하였다.
결과: 술 전 평균 황반하 할러층두께, 황반하 맥락막두께, 중심황반두께는 각각 214.28 ± 80.00 μm, 307.89 ± 96.30 μm, 525.64 ± 133.24 μm였으며, 술 후 1개월에 199.56 ± 75.76 μm, 290.36 ± 94.63 μm, 409.72 ± 98.45 μm로 술 전과 비교하여 모두 유의하게 감소하였다(각각 p=0.001, p<0.001, p<0.001). 술 전 황반하 할러층두께는 술 후 1개월 뒤 최대교정시력과 유의한 상관관계가 있었으며, 술 전 황반하 할러층두께가 두꺼울수록 술 후 최대교정시력이 좋았다(ρ=-0.342, p=0.041).
결론: 당뇨황반부종 환자에서 첫 유리체강 내 애플리버셉트 주입술 후 1개월째 관찰하였을 때, 술 전과 비교하여 황반하 할러층두께, 황반하 맥락막두께, 중심황반두께 모두 유의한 감소가 있었으며, 술 전 두꺼운 할러층두께는 좋은 단기적 술 후 최대교정시력 예측인자가 될 것으로 보인다.

참고문헌 (Reference)

1 황재형 ; 박새미 ; 김철구 ; 김종우 ; 김재휘, "당뇨황반부종을 대상으로 한 유리체강내 애플리버셉트 치료의 단기 효과" 한국망막학회 6 (6): 34-40, 2021

2 Campos A, "Viewing the choroid : where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema" 95 : 446-459, 2017

3 Klein R, "The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema" 91 : 1464-1474, 1984

4 Bahrami B, "Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema" 255 : 1133-1140, 2017

5 Giorno P, "Retinal-choroidal changes after intravitreal ranibizumab in diabetic macular edema : 12months follow-up" 55 : 576-, 2014

6 Endo H, "Relationship between diabetic macular edema and choroidal layer thickness" 15 : e0226630-, 2020

7 Hidayat AA, "Light and electron microscopic observations of seven cases" 92 : 512-522, 1985

8 Chen YY, "Intravitreal aflibercept for patients with diabetic macular edema refractory to bevacizumab or ranibizumab : analysis of response to aflibercept" 6 : 250-255, 2017

9 Funatsu H, "Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema" 133 : 70-77, 2002

10 Schmidt-Erfurth U, "Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists(EURETINA)" 237 : 185-222, 2017

11 Glassman AR, "Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema(Protocol T Extension Study)" 127 : 1201-1210, 2020

12 Bayhan HA, "Evaluation of the macular choroidal thickness using spectral optical coherence tomography in pseudoexfoliation glaucoma" 25 : 184-187, 2016

13 Spaide RF, "Enhanced depth imaging spectral-domain optical coherence tomography" 146 : 496-500, 2008

14 Okamoto M, "Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema" 256 : 885-892, 2018

15 Kniggendorf VF, "Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT" 79 : 155-158, 2016

16 Manjunath V, "Effect of focal laser and anti-VEGF therapy on choroidal thickness in diabetic macular edema as measured by enhanced-depth imaging optical coherence tomography" 54 : 2363-, 2013

17 Yiu G, "Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema" 158 : 745-751, 2014

18 Vujosevic S, "Diabetic macular edema with and without subfoveal neuroretinal detachment : two different morphologic and functional entities" 181 : 149-155, 2017

19 Laíns I, "Choroidal thickness in diabetic retinopathy : the influence of antiangiogenic therapy" 34 : 1199-1207, 2014

20 Endo H, "Choroidal thickness in diabetic patients without diabetic retinopathy : a meta-analysis" 218 : 68-77, 2020

21 Campos A, "Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema" 256 : 1857-1865, 2018

22 Hamadneh T, "Choroidal changes in diabetic patients with different stages of diabetic retinopathy" 12 : e10871-, 2020

23 Gupta P, "Characterisation of choroidal morphological and vascular features in diabetes and diabetic retinopathy" 101 : 1038-1044, 2017

24 Lee SH, "Changes of choroidal thickness after treatment for diabetic retinopathy" 39 : 736-744, 2014

25 Kim JT, "Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2diabetic patients" 54 : 3378-3384, 2013

26 Nourinia R, "Changes in central choroidal thickness after treatment of diabetic macular edema with intravitreal bevacizumab correlation with central macular thickness and best-corrected visual acuity" 38 : 970-975, 2018

27 Kaur C, "Blood-retinal barrier in hypoxic ischaemic conditions : basic concepts, clinical features and management" 27 : 622-647, 2008

28 Papadopoulos N, "Binding and neutralization of vascular endothelial growth factor(VEGF)and related ligands by VEGF Trap, ranibizumab and bevacizumab" 15 : 171-185, 2012

29 Dweikat A, "Baseline subfoveal choroidal thickness as a predictor for response to short-term intravitreal bevacizumab injections in diabetic macular edema" 15 : 4175-4180, 2021

30 Rayess N, "Baseline choroidal thickness as a short-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion" 103 : 55-59, 2019

31 Rayess N, "Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema" 159 : 85-91, 2015

32 Adhi M, "Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography" 131 : 1267-1274, 2013

33 Yazici A, "Alterations of choroidal thickness with diabetic neuropathy" 57 : 1518-1522, 2016

34 Endo H, "Alteration of layer thickness in the choroid of diabetic patients" 46 : 926-933, 2018

35 Wells JA, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema" 372 : 1193-1203, 2015